Research Corporation Technologies, Inc.

RCT invests primarily in start-up and early-stage companies with technologies that have the potential to become significant biomedical products. The organization concentrates on two main sectors: Biotechnology (including therapeutics and tools) and Medical Devices. RCT's investment strategy is characterized by flexible, long-term funding options, with initial financial commitments typically ranging from $500,000 to $5 million.

The firm seeks to partner with companies that demonstrate innovative approaches to healthcare challenges, particularly those emerging from universities and research institutions. RCT's investment thesis emphasizes the importance of supporting technologies that can lead to substantial improvements in patient care and treatment outcomes.

Research Corporation Technologies has supported a variety of notable ventures, including:

• Option 3: A medical device development vehicle focused on less complex medical device products.
• Therapeutic Human Polyclonals, Inc. (THP): A biotherapeutics company that developed a transgenic mammalian platform for creating human antibodies, later acquired by Roche.
• VasoNova, Inc.: A medical device company that developed an algorithm-based system for guiding vascular access device placement.

Additionally, RCT is associated with significant biomedical technologies such as:

• Cisplatin and Carboplatin: Widely prescribed anticancer drugs discovered through research at Michigan State University.
• Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF): A discovery with applications in preventing infections in patients undergoing chemotherapy.
• VIMPAT® (lacosamide): A medication for the treatment of epileptic seizures.

Jeffrey E. Jacob: Chairman of RCT, bringing extensive experience in technology transfer and investment management.

Shaun A. Kirkpatrick: President of Biotechnologies, with a background in biotech investments and development.

Christopher P. Martin: President of Medical Devices and Chief Financial Officer, overseeing financial operations and medical device investments.

Kathleen M. Hunter-Gregory: Controller, responsible for financial reporting and compliance.

Chad W. Souvignier, Ph.D: Vice President, contributing expertise in biomedical research and technology commercialization.

David A. Wiersma: Senior Associate, involved in deal sourcing and portfolio management.

Jorge Figueroa: Systems Administrator, managing IT infrastructure and support.

Brad Morie: Senior Director of Biotechnologies, focusing on biotech investments and strategy.

Danielle Wilson: Director of Administration & Corporate Secretary, overseeing administrative functions.

Paul Hoerbelt: Director of Biotechnologies, contributing to biotech investment strategies.

Maggie Zhou: Associate Controller, assisting in financial management.

William Kelly: Associate, supporting various operational and investment activities.

To pitch to Research Corporation Technologies, startups should submit their proposals through the application portal on RCT's website at rctech.com. It is advisable to include a detailed overview of the technology, its market potential, and the team behind the project. RCT appreciates clear and concise presentations that highlight the innovation and feasibility of the proposed solution.

Response times may vary, but founders can expect to hear back regarding their submissions within a reasonable timeframe. Warm introductions are beneficial but not strictly necessary for initial pitches.

Research Corporation Technologies has been actively engaged in the venture capital space, focusing on investments in biomedical innovation. Recent blog posts indicate ongoing involvement with industry developments, including updates on manufacturing expansions and partnerships. However, specific details regarding recent investments or exits have not been disclosed.